China’s CNBG, Aeras Of U.S. Join To Develop All-Inclusive TB Vaccine
This article was originally published in PharmAsia News
China National Biotech Group and Aeras, a U.S.-based institute, agreed to combine resources to develop a new vaccine against tuberculosis before existing drugs run out.
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.